Genetic risk for neurodegenerative disorders, and its overlap with cognitive ability and physical function - PubMed (original) (raw)

Genetic risk for neurodegenerative disorders, and its overlap with cognitive ability and physical function

Saskia P Hagenaars et al. PLoS One. 2018.

Abstract

Neurodegenerative disorders are associated with impaired cognitive function and worse physical health outcomes. This study aims to test whether polygenic risk for Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), or frontotemporal dementia (FTD) is associated with cognitive function and physical health in the UK Biobank, a cohort of healthy individuals. Group-based analyses were then performed to compare the top and bottom 10% for the three neurodegenerative polygenic risk scores; these groups were compared on the cognitive and physical health variables. Higher polygenic risk for AD, ALS, and FTD was associated with lower cognitive performance. Higher polygenic risk for FTD was also associated with increased forced expiratory volume in 1s and peak expiratory flow. A significant group difference was observed on the symbol digit substitution task between individuals with high polygenic risk for FTD and high polygenic risk for ALS. The results suggest some overlap between polygenic risk for neurodegenerative disorders, cognitive function and physical health.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1

Fig 1. Heat map of associations between the polygenic profile scores for neurodegenerative disease and cognitive ability and physical health.

Stronger associations are indicated by darker shades, red indicates a positive association, blue indicates a negative association. AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; TMT B-A, trail-making part B–part A; TMT B, trail making part B; TMT A, trail making part A; DSS, digit symbol substitution; VNR, verbal numerical reasoning; FVC, forced vital capacity; PEF, peak expiratory flow; FEV1, forced expiratory volume in 1s. *, significant association after FDR correction (p-value ≤ 0.018 (AD), 0.024 (ALS), or 0.0041 (FTD)). Full results can be found in S1 Table.

Similar articles

Cited by

References

    1. Prince M, Knapp M, Guerchet M, McCrone P, Prina M, Comas-Herrera A, et al. Dementia UK: Update 2014. Available from: http://www.cfas.ac.uk/files/2015/07/P326_AS_Dementia_Report_WEB2.pdf
    1. Alzheimer's Association. 2017 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2017;13(4):325–73.
    1. Hardy J, Selkoe DJ. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. Science. 2002;297(5580):353–6. doi: 10.1126/science.1072994 - DOI - PubMed
    1. Jack CR, Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55(4):484–90. doi: 10.1212/wnl.55.4.484 - DOI - PMC - PubMed
    1. Jack JCR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(5):1355–65. doi: 10.1093/brain/awp062 - DOI - PMC - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources